DNA Nanobots Raises $3.5 Million to Advance Non-Viral Gene Therapy Platform
Photo Credit: DNA Nanobots
Corporate Business News Sponsored by Business Watch Global
COLUMBUS, Ohio, January 5, 2026 (VSNewsNetwork.com) — Biotechnology company DNA Nanobots has secured $3.5 million in funding from a family office. According to the company, the investment is intended to support platform development and operations over the next 18 months.
The funding represents a portion of a planned $5 million Seed round and is expected to support advancements in its non-viral gene delivery platform. The capital will be used to advance pre-clinical studies, expand in-house manufacturing capabilities, strengthen its intellectual property portfolio, and support strategic hiring across molecular biology, nanotechnology, and engineering roles.
“We are very pleased to have successfully completed $3.5 million of our $5 million Seed round. This financing provides the capital needed to advance our programs and execute key value-creating milestones in 2026. We are grateful for the strong support from our investors who have re-invested and share our vision and confidence in our strategy and team,” said Jim Lynch, Chief Executive Officer of DNA Nanobots.
@VSNewsNetwork
•
@VSNewsNetwork •
The investment drew attention from Ohio’s life sciences community.
“We’re excited to see Ohio Life Sciences member DNA Nanobots secure $3.5 million in funding, a strong signal of confidence in Ohio’s life sciences ecosystem. It’s encouraging to see capital flowing into Ohio-based companies, including innovative Ohio State spinouts that showcase the strength of our research, commercialization, and homegrown innovation,” said Eddie Pauline, President and Chief Executive Officer of the Ohio Life Sciences Association.
DNA Nanobots is seeking an additional $1.5 million to complete its Seed round, which would support IND-enabling studies and preparation for first-in-human clinical trials.
For more information, visit www.dnananobots.com.
